Studies related to Viral Load and Alanylglutamine

Improvement Of Intestinal Permeability With Alanyl-glutamine In HIV Patients: A Randomized, Double Blinded, Placebo-controlled Clinical Trial

Effect None
Trial Design Double blind
Trial Length 1-2 Weeks
Number of Subjects 37
Sex Both Genders
Age Range 30-44
Body Types Average
Notes for this study:
Supplementation of a high dose of alanylglutamine (24g) daily for 10 days in subjects with HIV noted that supplementation, relative to glycine placebo, improved intestinal permeability as assessed by a lactulose:mannitol ratio but only in subjects reporting diarrhea in the last two weeks. No other biochemical effects of supplementation were observed.